#fertility-benefits

[ follow ]
#glp-1-drugs #healthcare-analyst-ratings #novo-nordisk-settlement #pharmaceutical-pricing #ivf #drug-pricing
Healthcare
from24/7 Wall St.
4 days ago

Barclays Raises Hims & Hers (HIMS) Target to $29 After Novo Deal Clears Legal Overhang - Canaccord Cuts Progyny (PGNY) on Cautious 2026 Outlook

Barclays raised Hims price target to $29 after Novo Nordisk deal removed legal risk, while Canaccord cut Progyny target to $19 citing uncertain 2026 outlook.
US news
fromThe Washington Post
4 months ago

White House releases plan to broaden access to IVF, fertility drugs

The Trump administration will encourage employer-provided fertility benefits and cut IVF drug prices via a pricing deal and discounts through TrumpRx.gov.
[ Load more ]